Kornimate/medical-research-clean huggingface dataset:
the child trial: hypoplastic left heart syndrome study.

Conditions: Hypoplastic Left Heart Syndrome

Summary: the objectives of this pilot study are to evaluate the feasibility and safety of intramyocardial injection of autologous c-kit+ cells during the stage ii bdcpa operation and to observe effects on clinical outcome including right ventricular myocardial function, severity of tricuspid regurgitation, incidence of serious adverse events, re-hospitalizations, changes in health status, the need for transplantation, or mortality.


Eligibility criteria:
inclusion criteria: * for inclusion in the study, subjects must meet all of the inclusion criteria: 1. subjects with hypoplastic left heart syndrome (all types) requiring stage i norwood operation. exclusion criteria: * candidates will be excluded from the study if any of the following conditions are met: 1. subjects undergoing the stage i norwood operation who do not have hlhs. 2. subjects requiring mechanical circulatory support immediately prior to stage ii bdcpa operation (within 5 days). 3. parent or guardian unwilling or unable to comply with necessary follow-up(s). 4. mother is serum positive for hiv 1/2, hepatitis bsag or viremic hepatitis c and treponema pallidum. 5. subjects who are unsuitable for inclusion in the study in the opinion of the investigator(s).

Keywords: stem cells pediatric
endoplasmic reticulum stress and resistance to treatments in ph-negative myeloproliferative neoplasms

Conditions: Polycythemia Vera; Essential Thrombocythemia

Summary: the aim of this study is to evaluate the endoplasmic reticulum stress markers as predictive for response to hydroxyurea in polycythemia vera (pv) and essential thrombocythemia (et).

the recent discovery of calreticulin mutations in myeloproliferative neoplasms point to the unexpected role of the endoplasmic reticulum biology in the pathophysiology in these diseases. otherwise, the association of endoplasmic reticulum stress with solid cancers, in particular in resistance to chemotherapy, is well documented, contrary to hematological malignancies. the study aims to evaluate endoplasmic reticulum stress markers as predictors for the response to hydroxyurea in polycythemia vera and essential thrombocythemia patients. the main objective is to correlate endoplasmic reticulum stress (defined as splicing of xbp1 above 30%) to the rate of complete response after 6 months according to the 2009 eln criteria. this is an observational retrospective study.

Eligibility criteria:
inclusion criteria: * et or pv patients diagnosed before acceleration phase and treated by hydroxyurea with a follow up period of at least 6 months following treatment start. * diagnosis criteria of pv : * who criteria of pv with : * acquired jak2v617f mutation \> 5% * absence of evident cause of secondary polycythemia * diagnosis criteria of et : * platelet count \> 450 g/l * absence of pv or chronic myeloid leukemia * bone marrow biopsy preferred but not necessary in absence of reactional causes (crp and ferritin levels normal) and/or presence of acquired jak2v617f, calr exon 9 or mpl exon 10 * availability of rna sample of total leukocytes before start of treatment. exclusion criteria: in absence of clonality marker, presence of secondary cause of : * thrombocytosis : * inflammatory syndrom (crp or sv increased) * iron deficiency (decreased ferritin level or increased soluble transferrin receptor level) * polycythemia : * increased or normal level of epo in context of : * hypoxia, respiratory insufficiency * sleep apnea syndrome * hyperaffin hemoglobin * absence of treatment by hydroxyurea * treatment by anagrelide, p32, pipobroman, interferon without subsequent hydroxyurea treatment. * concommitant treatment by other cancer chemotherapy (in a context of solid cancer for example). * diagnostic during transformation to acute leukemia * treatment by hydroxyurea during less than 6 months * bad observance of the cytotoxic treatment

Keywords: myeloproliferative neoplasms endoplasmic reticulum stress
potential use of indocyanine green as a fluorescent agent for definition of surgical margins in cancer

Conditions: Malignant Neoplasm

Summary: the surgeon may remove a very small amount of additional tissue compared to what would be removed if you were not enrolled in the study. this tissue may prove to contain tumor or it may contain normal tissue. the surgical cavity will be examined by a special laser pen after the tumor is removed, and if areas of fluorescence are seen, that may indicate tumor cells where the icg dye collected are still remaining and the surgeon would then remove those. after the tumor and the tissue around it are removed and sent to the laboratory, the tissue may be examined using that same laser pen to see where the cancer cells are and compare that to what the laboratory sees when it looks at the tumor and tissue with a microscope. it is hoped that what the dye shows and what is seen with the microscope will be alike.

primary objectives: i. to validate the use of intraoperative indocyanine green (icg) for better definition of tumor margins therefore, minimizing the necessity of a second surgical procedure to obtain negative margins. outline: patients receive indocyanine green solution intravenously (iv) between 2-8 hours before surgery. fluorescence measurements are taken from all specimens removed during surgery. after completion of study, patients are followed up at 48 hours.

Eligibility criteria:
inclusion criteria: patients with a tumor that will be treated surgically. exclusion criteria: * patients with a known history of reaction to iodine or iodine-containing compounds. * pregnant women. any patients found to be pregnant will be excluded from the study.
impact of exercise training on exercise capacity in patients with severe chronic heart failure

Conditions: Heart Failure

Summary: patients with heart failure are limited in their exercise capacity due to skeletal muscle alteration and an impairment of peripheral perfusion. regular physical exercise training has been shown to partially correct these peripheral maladaptations in patients with stable heart failure, which was associated with an improvement in exercise capacity. however, it is unknown so far, whether regular physical activity also exerts beneficial effects in patients with severe chronic heart failure. aim of the trial is therefore to assess the effects of aerobic exercise training on exercise capacity, muscle maladaptations and peripheral perfusion in patients with severe chronic heart failure according to nyha class iii b.

a total of 36 patients with severe chronic heart failure are prospectively randomized to either 3 months of aerobic ergometer training or a sedentary control group. before and after the intervention period maximal exercise capacity is assessed by ergospirometry, endothelial function is determined by high-resolution a-mode ultrasound, and muscle mass is determined by ct. skeletal muscle biopsies are obtained at begin and after 3 months and are analyzed for markers of muscle catabolism/anabolism.

Eligibility criteria:
inclusion criteria: * chronic heart failure (nyha class iii b) * peak oxygen uptake \<20 ml/min/kg body weight * left ventricular ejection fraction \<25 % * left ventricular end-diastolic diameter \>60 mm exclusion criteria: * exercise-induced myocardial ischemia * cardiac decompensation within the last 8 weeks * ventricular arrhythmias (\>lown 4b) in patients not protected by an icd * insulin-dependent diabetes mellitus * uncontrolled arterial hypertension * orthopedic conditions excluding training participation * body mass index \>30 kg/m2

Keywords: chronic heart failure exercise training
effectiveness study of resection of primary tumor in stage iv colorectal cancer patients

Conditions: Colorectal Cancer Metastatic

Summary: there is still no perfect treatment suggestion for patients with asymptomatic colorectal cancer with unresectable metastatic disease. whether patients can benefit from palliative resection of primary tumor or not is still waiting for answer. the investigators hypothesis that asymptomatic metastatic colorectal cancer patients who respond to chemotherapy will benefit from primary tumor resection.


Eligibility criteria:
inclusion criteria: * 18 to 70 years old * both genders * ecog:0-2 score * pathological confirmed colon cancer or rectal cancer with at least 12 cm far away from anal verge * ct,mri,or pet-ct confirmed metastasis * mdt confirmed unresectable metastasis lesion * no evidence of obstruction, bleeding, perforation * wbc≥4.0×109/l，neu ≥2.0×109/l，plt≥100×109/l * no contraindication for chemotherapy * no evidence of other malignant tumor * expected survival time \> 6 months exclusion criteria: * mcrc patients who did not respond to first line chemotherapy * require surgical intervention during the primary tumor-related symptoms * obvious coagulopathy * severe heart, liver, kidney damage or other serious uncontrolled medical illness or acute infection, cachexia * severe organ damage after chemotherapy, surgery or unable to continue to systemic chemotherapy * pregnant or lactating women or women of childbearing age who refuse to accept contraception. * nearly three months participated in clinical trials of other persons. * mental abnormalities

Keywords: metastasis colorectal cancer chemotherapy resection of primary tumor
intensive preoperative speech rehabilitation in drug-resistant temporal epilepsy

Conditions: Epilepsy; Anomia; Temporal Lobe Epilepsy

Summary: out of 30,000 new cases per year in france, 30% of epileptic patients are drug-resistant. neurosurgery, which consists in resecting the epileptogenic zone, is the only chance of cure. in the case of temporal epilepsy of the language-dominant hemisphere (tle), this procedure presents a high risk of increasing cognitive difficulties and may even be contraindicated for this reason alone. the difficulties found are impairments in lexical access (anomia) and verbal memory and affect more than 60% of patients . preoperative cognitive rehabilitation could influence brain plasticity mechanisms but there are currently no recommendations on this topic. in this context, the investigators have developed a speech rehabilitation procedure specific to the needs of eltpr patients. they rely on cognitive hypotheses explaining the disorders but also on models of rehabilitation-induced neural plasticity likely to improve cognitive reserve before surgery. the investigators hypothesize that preoperative cognitive language rehabilitation in eltpr patients may decrease surgical risk and improve postoperative language prognosis. the primary objective is to demonstrate the protective efficacy of preoperative speech rehabilitation on language performance postoperatively.


Eligibility criteria:
inclusion criteria: 1. patient 16 years of age and older, 2. patient whose epileptogenic area involves the temporal structures of the hemisphere specialized for language, 3. patient whose hemispheric specialization for language is known 4. patient willing to undergo resective surgery such as anterior temporal lobectomy or resection in the temporal lobe involving the hippocampus and/or the baso-temporal language area and whose planned surgery date is compatible with the performance of the study, 5. patient with a known ntb score 6. patient who has signed an informed consent or patient whose parents or legal guardians have signed the informed consent (or a single parent or legal guardian if applicable) 7. patient whose first language is french (1st language learned by the patient), 8. patient declaring to be familiar with the use of a computer and having access to an internet connection from home 9. patient affiliated or benefiting from a social security system. exclusion criteria: 1. patient with a speech disorder that may impair intelligibility and compromise the use of the interface; 2. patient with an uncorrected hearing impairment, 3. patients with a total intelligence quotient (iq) \<70 (assessed in the context of care, in the year preceding the surgical procedure) 4. patients who are pregnant, nursing, deprived of liberty, under guardianship or curatorship.
study of iressa in patients with relapsed or refractory acute myelogenous leukemia

Conditions: Myelogenous Leukemia, Acute

Summary: the purpose of this study is to determine how effective, and to what extent, iressa is in the treatment of acute myelogenous leukemia.

patients will receive iressa daily until either disease progression or intolerable toxicity develops. on day 1 of treatment, a physical exam and bloodwork will be performed. once weekly for the first 8 weeks, a physical exam and complete blood count with differential will be performed. for the first year, a physical exam, bloodwork will be performed monthly. bone marrow biopsies will be performed after the first month of therapy and then every 3 months for the first year. after the first year a physical exam, bloodwork will be performed every 3 months and bone marrow biopsies every 6 months.

Eligibility criteria:
inclusion criteria: * patients must have pathologically documented acute myelogenous leukemia and either not be a candidate for myelosuppressive chemotherapy due to age or comorbid disease; or have relapsed acute myelogenous leukemia or be refractory to standard therapy and not likely to require cytoreductive therapy within 30 days. * ecog performance status 0, 1 or 2 * age \> 18 years * adequate kidney and hepatic function * greater than 4 weeks from any chemotherapy, radiotherapy, immunotherapy, or systemic steroid therapy with the exception of hydroxyurea. * greater than 2 months following bone marrow or peripheral blood stem cell transplantation or donor lymphocyte infusion. exclusion criteria: * uncontrolled active infection * urgent need for cytoreductive chemotherapy, surgery, or radiotherapy * current chemotherapy or chemotherapy within the last 4 weeks. * pregnancy or nursing mothers * infection with hiv

Keywords: aml acute myelogenous leukemia gefitinib iressa
11c methionine pet for the detection of hyperfunctional parathyroid tissues

Conditions: Primary Hyperparathyroidism

Summary: the overall sensitivity and specificity of 11c-met pet/ct is superior to 18f-fdg pet/ct and conventional spect-ct for the detection of abnormal parathyroid glands.

study objectives primary: to compare the accuracy, sensitivity and specificity of 11c-methionine (met) pet/ct and 99mtc-mibi spect-ct in the detection of pathologic parathyroid glands in patients with primary hyperparathyroidism. secondary:to compare the accuracy, sensitivity and specificity of 11c-met and 18f-fdg pet/ct scans in the detection of pathologic parathyroid glands in patients with primary hyperparathyroidism. study design a phase ii diagnostic imaging, single-centre study to compare the accuracy of 11c-met pet/ct with standard 99mtc-mibi spect-ct and with 18f-fdg pet/ct imaging in patients with primary hyperparathyroidism. study population number of subjects: 50 patients number of groups: 1: 50 with primary hyperparathyroidism. age/gender: age greater than or equal to 19 years / male and female study specific requirements: subjects with clinically suspected primary hyperparathyroidism who require 99mtc-mibi spect-ct parathyroid imaging. investigational product product: 11c-methionine route of administration: intravenous dosage(s) and frequency: radioactive dose of 11c-methionine of 6 mbq per kilogram body weight per injection (maximum dose of 555 mbq); one injection per patient. comparator products product: 99mtc-methoxyisobutylisonitrite; 18f-fluorodeoxyglucose route of administration: intravenous dosage(s) and frequency: (1) radioactive dose of 99mtc-methoxyisobutylisonitrite of 555 - 740 mbq per injection; one injection per patient. (2) radioactive dose of 18f-fluorodeoxyglucose of 296 - 521 mbq per injection; one injection per patient. evaluation criteria efficacy: the comparison of the accuracy, sensitivity, and specificity of 11c-met pet/ct with 99mtc-mibi spect-ct and 18f-fdg pet/ct in the detection of pathologic parathyroid glands in patients with primary hyperparathyroidism. safety: vital signs before and following 11c-met administration; adverse events collection.

Eligibility criteria:
inclusion criteria: * adults \> age 18; * able to provide written informed consent; * subjects with biochemical evidence, including elevated serum calcium and pth levels, of primary hyperparathyroidism. exclusion criteria: * subjects with previous successful parathyroidectomy and parathyroid tissue reimplantation; * pregnancy; * subjects who are unable to tolerate the physical/logistical requirements of completing two pet/ct scans, including lying still for a prolonged period of time and receiving two intravenous injections. * subjects who exceed the safe weight limit of the pet/ct bed (204.5 kg) or who cannot fit through the pet/ct machine (diameter 70cm).
a registry for hereditary cancer risk assessment and genetic testing

Conditions: Prostate Cancer

Summary: this prospective registry will evaluate the feasibility and impact of implementing standard cancer family history review and guideline-aligned genetic testing for men diagnosed with prostate cancer in community urology practices nationwide.

genes linked to hereditary cancer syndromes have been associated with increased risk for prostate cancer (prca), earlier disease onset and increased disease aggressiveness.1,2 ascertaining family cancer history and hereditary risk in men diagnosed with prca can help inform medical management decisions. recently published national comprehensive cancer network (nccn) clinical practice guidelines in oncology for prostate cancer (v3.2018)3 and genetic/familial high risk assessment: breast and ovarian (v2.2019)4 as well as the american urological association guideline for clinically localized prostate cancer (2017)5 recommend appropriate counseling and genetic testing for men who are at increased hereditary cancer risk, based upon personal or family history. genetic testing for patients with metastatic prostate cancer is now standard of care per nccn genetic/familial high risk assessment: breast and ovarian (v2.2019) guidelines4. nccn prostate cancer guidelines (v3.2018)3 recommend obtaining a cancer-focused family history at diagnosis and consideration of germline genetic testing in multiple risk groups. community urology practices can support guideline-aligned care by performing routine hereditary cancer risk assessment (hcra), patient counseling and, when appropriate, genetic testing. this prospective registry will evaluate the feasibility and impact of implementing standard cancer family history review and guideline-aligned genetic testing for men diagnosed with prca in community urology practices nationwide.

Eligibility criteria:
inclusion criteria: * 18 years of age or older at time of enrollment * affected with prostate cancer (newly or previously diagnosed patients). * presents for a medical care visit and meets eligibility criteria for hereditary cancer genetic testing, based on personal and family cancer history and nccn practice guidelines in oncology (prostate cancer) * able to understand informed consent and agrees to participate in the registry. exclusion criteria: * minors (younger than 18 years of age) * have had previous genetic testing for hereditary breast and ovarian cancer or lynch syndrome, or have previously undergone hereditary multi-gene, pan-cancer, or panel testing. * unable to provide routine clinical informed consent.

Keywords: prostate cancer patients myrisk genetic testing
attenuation of the hemodynamic response to double-lumen endotracheal intubation with nebulized lidocaine

Conditions: Lung Neoplasms

Summary: the goal of this clinical trial is to test the effect of nebulized lidocaine on the hemodynamic response in the participant undergoing double-lumen endotracheal intubation. the main question it aims to answer is to evaluate the changes in mean arterial pressure after intubation. participants will inhale 5ml of 2% lidocaine by nebulization15min before intubation. researchers will compare saline group to see if saline effects


Eligibility criteria:
inclusion criteria: 1. aged 18-65 years, american society of anesthesiologists class i-ii 2. participants undergoing double-lumen endotracheal intubation under general anesthesia 3. signed informed consent and volunteered to participate in the experiment exclusion criteria: 1. poor control of hypertension 2. preoperative arrhythmia 3. severe coronary artery or heart valve disease 4. sequelae of cerebrovascular accident 5. severe lung, liver, kidney and immune system diseases 6. suspected difficult airway 7. confirmed or suspected allergy to this trial drug 8. as judged by the investigator to be ineligible for the study, such as communication impairment (language or intelligence)

Keywords: double-lumen endotracheal intubation
the effect of acute resistance exercise on inhibitory control

Conditions: Exercise; Cognitive Function

Summary: the current study is a five-arm, single bout program aiming to assess the effects of training volume and intensity of acute resistance exercise on inhibitory control on neurocognitive function with respect to event-related potential in adults aged 20 - 26 years.

the current study is expected that 175 healthy adults will be recruited and randomly assigned to control group, low volume-moderate intensity, moderate volume-moderate intensity, high volume-moderate intensity, or moderate volume-low intensity group, with 35 participants in each group. participants will be required to conduct two experiments. the first was the familiarity experiment, which consisted of the experiment description, the familiarity test, and the 6 repetition maximum (rm) test. the process lasted about 3 hours. the exercise group was given a warm-up exercise before the intervention, followed by resistance exercise, including bench press, rowing, deadlift, and squat, all completed on the smith machine. after the exercise, the group was given a cool down, while the control group was given 30 minutes of reading. before and after the intervention, stroop, event-related potential and fingertip blood lactate were measured, and another fingertip blood lactate was measured 10 minutes after the intervention, which lasted about 3 hours.

Eligibility criteria:
inclusion criteria: * the dominant hand is right-handed * 18.5 \< bmi \< 26 * can cooperate with fingertip blood collection * no color blindness and epilepsy * not taking medications that affect brain function * irregular exercise (more than 150 minutes per week for 3 months) exclusion criteria: * the participants who do not meet the inclusion or the physical activity readiness questionnaire for everyone (par-q+) criteria.

Keywords: acute resistance exercise inhibitory control training volume intensity event-related potential